Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tamibarotene - Nippon Shinyaku/Syros Pharmaceuticals/Toko Pharmaceutical

Next Previous
Drug Profile

Tamibarotene - Nippon Shinyaku/Syros Pharmaceuticals/Toko Pharmaceutical

Alternative Names: AM-80; Amnoid; Amnolake; INNO-507; NSC-608000; OMS0728; OP-01-Nippon Shinyaku/Syros Pharmaceuticals/Toko Pharmaceutical; Oral RARa agonist - Syros Pharmaceuticals; Retinobenzoic acid; RR-110; SY-1425; Tamibaro; Tamibarotene; TM-411; TOS-80T; Z-208

Latest Information Update: 11 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shionogi
  • Developer Childrens Hospital Los Angeles; CytRx Corporation; Gyre Therapeutics; Nagoya University; Nippon Shinyaku; Ohara Pharmaceutical; Syros Pharmaceuticals; TMRC Co. Ltd; Toko Pharmaceutical Industrial; Zeria
  • Class Antineoplastics; Benzoates; Retinoids; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Retinoic acid receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute promyelocytic leukaemia
  • Phase III Myelodysplastic syndromes
  • Phase II Acute myeloid leukaemia
  • Phase I/II Pancreatic cancer
  • No development reported Neutropenia; Solid tumours
  • Discontinued Crohn's disease; HER2 positive breast cancer; Liver cancer; Non-small cell lung cancer; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 10 Apr 2024 Tamibarotene - Nippon Shinyaku/Syros Pharmaceuticals/Toko Pharmaceutical receives Fast Track designation for Acute myeloid leukaemia [PO] (Combination therapy, First-line therapy) in USA
  • 27 Mar 2024 Syros Pharmaceuticals has patents pending for Tamibarotene in the US, the Europe, Japan, Australia, Canada, China, Russia, Israel and Mexico
  • 27 Mar 2024 Syros Pharmaceuticals anticipates to launch tamibarotene for Myelodysplastic syndrome (HR-MDS) in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top